Riskpilot← Back to searchSign inGet full accessRYEN LEGEKONTOR AS
ASActiveOrg 924685107Ryenstubben 3, 0679 OsloGeneral medical practice activities · NACE 8621Est. 20203 employees
Revenue 2024
NOK 3,9M
-14% vs 2023
EBITDA margin
-10.2%
-235% vs 2023
Equity ratio
3.2%
Financial strength
Net profit 2024
NOK -429K
-294% vs 2023
| Revenue | NOK 3,9M | -14% |
| EBITDA | NOK -400K | -235% |
| Net profit | NOK -429K | -294% |
| Total assets | NOK 940K | -41% |
| Equity | NOK 30K | -93% |
| Employees | 3 | — |
Legal name
RYEN LEGEKONTOR AS
Org number
924685107
Legal form
Aksjeselskap
NACE code
8621 · General medical practice activities
Founded
2. mars 2020
Share capital
NOK 30 000
Employees
3 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styret i fellesskap.
Company purpose
Kontorfellesskap for samarbeidende leger ved ryen legekontor.
Address
Ryenstubben 3, 0679 Oslo
Phone
+4723037880
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 4 045 | 4 213 | 4 503 | 4 597 | 3 936 |
| Staff expenses | −1 550 | −1 739 | −2 113 | −2 063 | −2 099 |
| EBITDA | 537 | 298 | 408 | 297 | −400 |
| Depreciation & amort. | −37 | −40 | −26 | −32 | −32 |
| EBIT | 501 | 258 | 382 | 265 | −431 |
| Net financials | −1 | −0 | 0 | −1 | 2 |
| Profit before tax | 500 | 258 | 382 | 264 | −429 |
| Tax | 111 | 60 | 151 | 43 | −0 |
| Net profit | 389 | 198 | 231 | 222 | −429 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 1 066 | 1 370 | 1 741 | 1 581 | 940 |
| Equity | 409 | 607 | 438 | 459 | 30 |
| Long-term debt | 174 | 174 | 174 | 174 | 131 |
| Short-term debt | 483 | 589 | 812 | 706 | 538 |
| Total debt | 657 | 763 | 986 | 880 | 668 |
EBITDA margin
-10.2%
This company
15.8%
Market median
-165% vs market
20202024
Equity ratio
3.2%
This company
38.2%
Market median
-92% vs market
20202024
Return on equity
-1419.8%
This company
18.4%
Market median
-7816% vs market
20202024
Net profit margin
-10.9%
This company
8.1%
Market median
-235% vs market
20202024
Asset turnover
4.19×
This company
1.12×
Market median
+274% vs market
20202024
Debt / equity
30.09×
This company
0.62×
Market median
-4753% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
KK Chief Executive Officer | Chief Executive Officer | 2024 |
| Former (1) | ||
TO Chief Executive Officer | Chief Executive Officer | 2020 – 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2020 | |
| Board of Directors | 2024 | |
| Board of Directors | 2025 | |
| Former (1) | ||
| Board of Directors | 2020 – 2025 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 25% | 25% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Oslo Health Clinic, Norsk Nevrokirurgisk, Allmenmedisinsk Og Idrettsmedisinsk Se
RYEN LEGEKONTOR AS (this company)Board members of RYEN LEGEKONTOR AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Kristian Kolmannskog | Chief Executive Officer | 0 companies |
| Theodor Omar Chammas Ellingsen | Chief Executive Officer | 0 companies |
| Sadia Ibrahim | Board of Directors | 0 companies |
| Adnan Walayat | Board of Directors | 0 companies |
| Kirsti Waage | Board of Directors | 0 companies |
| Kine Meum | Board of Directors | 0 companies |